Explorations into modeling human oral bioavailability.

Explorations into modeling human oral bioavailability started with a whole dataset of 772 drug compounds. First, training set and test set were chosen based on Kohonen's self-organizing Neural Network (KohNN). Then, a quantitative model of the whole dataset was built using multiple linear regression (MLR) analysis. This model had limited predictability emphasizing that a variety of pharmacokinetic factors influence human oral bioavailability. In order to explore whether better models can be built when the compounds share some ADME properties, four subsets were chosen from the whole dataset to build quantitative models and better models were obtained by MLR analysis. These studies show that, indeed, good models for predicting human oral bioavailability can be obtained from datasets sharing certain pharmacokinetic properties.

[1]  Andreas Zell,et al.  Locating Biologically Active Compounds in Medium-Sized Heterogeneous Datasets by Topological Autocorrelation Vectors: Dopamine and Benzodiazepine Agonists , 1996, J. Chem. Inf. Comput. Sci..

[2]  H. van de Waterbeemd,et al.  Property-based design: optimization of drug absorption and pharmacokinetics. , 2001, Journal of medicinal chemistry.

[3]  J J Baldwin,et al.  Prediction of drug absorption using multivariate statistics. , 2000, Journal of medicinal chemistry.

[4]  J. Gasteiger,et al.  ITERATIVE PARTIAL EQUALIZATION OF ORBITAL ELECTRONEGATIVITY – A RAPID ACCESS TO ATOMIC CHARGES , 1980 .

[5]  Johann Gasteiger,et al.  A new model for calculating atomic charges in molecules , 1978 .

[6]  Tingjun Hou,et al.  ADME Evaluation in Drug Discovery, 6. Can Oral Bioavailability in Humans Be Effectively Predicted by Simple Molecular Property-Based Rules? , 2007, J. Chem. Inf. Model..

[7]  Kenneth J. Miller,et al.  Additivity methods in molecular polarizability , 1990 .

[8]  Li Xing,et al.  Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat. , 2004, Journal of medicinal chemistry.

[9]  A. Beresford,et al.  The emerging importance of predictive ADME simulation in drug discovery. , 2002, Drug discovery today.

[10]  Yutaka Yoshida,et al.  Asymmetric synthesis of chiral spirocyclanes: Selective formation of 2-acyloxy-1-oxospiro[4.n]alkanes by regio- and stereoselective rearrangement of α,β-epoxy acylates in bicyclo[n.3.0]alkane systems , 1995 .

[11]  U. Christians,et al.  Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. , 1998, The Journal of pharmacology and experimental therapeutics.

[12]  J. Gasteiger,et al.  Autocorrelation of Molecular Surface Properties for Modeling Corticosteroid Binding Globulin and Cytosolic Ah Receptor Activity by Neural Networks , 1995 .

[13]  Binne Zwanenburg,et al.  A two-step chirality transfer from (−)-endo- to (−)-exo-tricyclo[5.2.1.026]deca-4,8-dien-3-one , 1993 .

[14]  I Moriguchi,et al.  Non-congeneric structure-pharmacokinetic property correlation studies using fuzzy adaptive least-squares: oral bioavailability. , 1994, Biological & pharmaceutical bulletin.

[15]  Johann Gasteiger,et al.  Quantitative models of gas-phase proton-transfer reactions involving alcohols, ethers, and their thio analogs. Correlation analyses based on residual electronegativity and effective polarizability , 1984 .

[16]  R. Fontana,et al.  Molecular and physical mechanisms of first-pass extraction. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[17]  Peter C. Jurs,et al.  Descriptions of molecular shape applied in studies of structure/activity and structure/property relationships , 1987 .

[18]  Johann Gasteiger,et al.  Neural networks in chemistry and drug design , 1999 .

[19]  Y Zhang,et al.  Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. , 1998, Journal of pharmaceutical sciences.

[20]  John G. Topliss,et al.  QSAR Model for Drug Human Oral Bioavailability1 , 2000 .

[21]  Hébert.  Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. , 1997, Advanced drug delivery reviews.

[22]  Morton B. Brown,et al.  Role of intestinal P‐glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine , 1997, Clinical pharmacology and therapeutics.

[23]  Tingjun Hou,et al.  ADME Evaluation in Drug Discovery, 7. Prediction of Oral Absorption by Correlation and Classification , 2007, J. Chem. Inf. Model..

[24]  J. Beijnen,et al.  The pharmacological role of P-glycoprotein in the intestinal epithelium. , 1998, Pharmacological research.

[25]  P. Jurs,et al.  Development and use of charged partial surface area structural descriptors in computer-assisted quantitative structure-property relationship studies , 1990 .

[26]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[27]  P. Selzer,et al.  Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. , 2000, Journal of medicinal chemistry.